Literature DB >> 26536384

Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.

Ifat Zerin Krase1, Kevin Cavanaugh2, Clara Curiel-Lewandrowski2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26536384     DOI： 10.1001/jamadermatol.2015.3405

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  Off-label studies on apremilast in dermatology: a review.

Authors:  Nolan J Maloney; Jeffrey Zhao; Kyle Tegtmeyer; Ernest Y Lee; Kyle Cheng
Journal:  J Dermatolog Treat       Date:  2019-04-02       Impact factor: 3.359

2.  Beneficial Impact of Apremilast on Palmoplantar Keratodermas.

Authors:  Kimiko Nakajima; Riho Nakajima; Hiroyuki Morisaka; Hideki Nakajima; Shigetoshi Sano
Journal:  Acta Derm Venereol       Date:  2021-04-26       Impact factor: 3.875

3.  Successful treatment of type II pityriasis rubra pilaris with secukinumab.

Authors:  Marie-Léa Gauci; Marie Jachiet; Jeremy Gottlieb; Isabelle Madeleine-Chambrin; Michel Rybojad; Martine Bagot; Jean-David Bouaziz
Journal:  JAAD Case Rep       Date:  2016-12-05

Review 4.  Management of refractory pityriasis rubra pilaris: challenges and solutions.

Authors:  Gaia Moretta; Erika V De Luca; Alessandro Di Stefani
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-11-09

Review 5.  The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.

Authors:  Yael Renert-Yuval; Emma Guttman-Yassky
Journal:  Adv Ther       Date:  2017-06-23       Impact factor: 3.845
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.